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the presented studies do not test the self-
renewal (serial transfer of neurospheres) 
or potency of glioma cells that are more 
rigorous analyses of the stem cell frac-
tion. Studies of glioma cells isolated from 
fresh samples of PN, Prolif, and Mes, sig-
nature tumors using more formal tests of 
stem cell function would better determine 
whether these expression profiles report 
the stem cell phenotype of HGG. These 
studies might also help to determine if the 
different expression subtypes of HGG are 
maintained by a common cell type, or rep-
resent more distinct forms of the disease 
that arise from transformed cells at differ-
ent stages along the neural differentiation 
pathway. Interestingly, the authors demon-
strate that some tumors display a switch 
in expression signature from PN to Mes 
following disease progression (Figure 1). 
Thus, expression subtypes of HGG may 
not be entirely distinct, but rather repre-
sent different stages or forms of a more 
common disease process. Comparison of 
the PN, Prolif, and Mes signatures to those 
of the available mouse models of glioma 
that have been derived from cells in dif-
ferent stages of differentiation (Bachoo et 
al., 2002) may provide further clues to the 
cellular origins of these HGG subtypes. 
Finally, the findings of Phillips et al. also 
have implications for the development 
of novel therapies of HGG. Perhaps the 
most significant of these is the demonstra-
tion that tumors with PN and Prolif/Mes 
signatures display evidence of activation 
of the NOTCH and AKT cell signal path-
ways, respectively. These cell signaling 
systems have been identified previously 
as potential targets for glioma treatment. 
Therefore, the efficiency of clinical trials 
that test inhibitors of NOTCH or AKT sig-
naling could be increased significantly by 
enrolling patients whose tumors display 
the PN or Prolif/Med expression signa-
ture, respectively.
The extensive expression profiling 
analysis by Phillips et al. represents an 
important step forward in our understand-
ing of the biology and treatment of HGG. 
Their integrated approach has provided 
important clues that may allow us ulti-
mately to identify the distinct molecular 
processes that result in the long-recog-
nized clinical and pathologic forms of 
these devastating diseases.
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Sphingosine-1-phosphate (S1P) is a pleiotropic lipid mediator that has been shown to regulate cell growth, cell survival, 
cell invasion, vascular maturation, and angiogenesis, processes that are important for cancer progression. In this issue of 
Cancer Cell, Visentin et al. demonstrate that a monoclonal antibody that binds S1P with extremely high affinity and specificity 
significantly slows tumor progression and associated angiogenesis in several animal models of human cancer. Their results 
suggest that S1P not only affects tumor cells themselves, but also is permissive or required for the actions of angiogenic 
factors, and thus may be a bona fide cancer target.Sphingosine-1-phosphate (S1P) is the 
simplest and most intriguing sphin-
golipid metabolite. Although S1P was 
initially considered as an intermedi-
ate in the ultimate degradation of all 
sphingolipids, its bewildering nature 148	is rapidly being deciphered, and it is 
now emerging as a vital lipid media-
tor of a myriad of cellular processes 
important for cancer. S1P exerts most 
of its actions as a specific ligand for a 
family of five cognate G protein-coupled receptors, designated S1P1–5, which 
regulate cytoskeletal rearrangements 
and cell movement, angiogenesis and 
vascular maturation, and immunity 
and lymphocyte trafficking. This potent 
lipid may also have intracellular func-cancer cell march	2006
	 p r e v i e w sFigure 1.	crosstalk	between	S1P	receptors	and	growth	and	proangiogenic	factor	receptors	can	
lead	to	the	amplification	of	signals	important	for	tumorigenicity	and	angiogenesis
In	addition	to	platelets	that	secrete	S1P,	growth	factors	(GF)	activate	rTKs,	causing	upregula-
tion	and	stimulation	of	SphK1	and	production	of	S1P	that	can	be	released	from	tumor	cells	by	
uncharacterized	mechanisms.	This	S1P	in	turn	can	act	in	an	autocrine	or	paracrine	manner	
to	activate	S1Prs	present	on	the	tumor	cell	or	on	endothelial	cells	and	stimulate	canonical	
signaling	downstream	of	heterotrimeric	G	proteins	and	can	also	transactivate	rTKs.	This	leads	
to	signal	amplification	loops	that	regulate	tumor	growth,	survival,	invasion,	vascular	remod-
eling,	and	angiogenesis.	It	is	also	possible	that	transactivation	of	S1Prs	and	rTKs	is	facilitated	
by	their	colocalization	mediated	by	a	scaffolding	protein	in	a	signaling	complex	(signalplex).	
Thus,	a	mab	that	neutralizes	S1P	could	slow	tumor	progression	and	angiogenesis	by	interfering	
at	multiple	sites	of	S1P	actions.	For	simplicity,	known	signaling	pathways	downstream	of	S1Prs	
or	rTKs	are	not	shown.tions important for calcium homeos-
tasis, cell growth, and suppression of 
apoptosis (Spiegel and Milstien, 2003). 
In contrast to prosurvival S1P, its pre-
cursors, sphingosine and ceramide 
(N-acyl sphingosine), have been asso-
ciated with growth arrest and apoptosis. 
Because these metabolites are inter-
convertible, their dynamic balance, the 
so-called “sphingolipid rheostat,” and 
their regulation of opposing signals 
can determine whether cells live or die. 
Thus, it is not surprising that increased 
S1P or attenuated sphingosine and/or 
ceramide levels have been implicated 
in various stages of cancer pathogen-
esis, including antiapoptotic phenotype, 
metastasis, escape from senescence, 
and resistance to chemotherapy and 
radiation therapy.
S1P levels in cells are low and tightly 
regulated both spatially and temporally. cancer cell march	2006	S1P is produced by phosphorylation of 
sphingosine by two sphingosine kinase 
isoenzymes (SphK1 and SphK2) and 
can be dephosphorylated by several 
phosphatases or cleaved irreversibly 
by a lyase. SphK1 may be oncogen-
ic, since it enhances cell growth and 
colony formation in soft agar, confers 
resistance to radiation and chemo-
therapy, and promotes tumorigenesis 
in nude mice. SphK1 is elevated in a 
variety of solid tumors, and inhibitors 
of SphK1 reduce gastric and mammary 
adenocarcinoma tumor growth in mice 
(French et al., 2003). One such inhibitor 
is now in clinical trials in patients with 
advanced solid tumors in combination 
with cisplatin.
Importantly, many growth and proan-
giogenic factors that have been impli-
cated in cancer progression, including 
EGF, PDGF, and VEGF, stimulate and translocate SphK1 to the plasma mem-
brane, resulting in local formation of 
S1P (Pitson et al., 2005) and activation 
of S1P receptors (S1PRs) (Spiegel and 
Milstien, 2003), such as S1P1, which 
plays a critical role in angiogenesis and 
vascular maturation (Liu et al., 2000). 
Binding of S1P to the S1P1 receptor 
can also increase PDGF and VEGF 
production, leading to transactivation 
of the growth factor receptors that in 
turn activate downstream signals that 
regulate vascular remodeling and cell 
movement. Despite these observations, 
until now there was no direct definitive 
evidence that S1P plays a critical role 
in tumor growth, metastases, and ang-
iogenesis. In this issue of Cancer Cell, 
Visentin et al. (2006) show that neutral-
izing S1P with a specific monoclonal 
antibody was remarkably effective in 
retarding progression of deadly and 
multiresistant cancers such as lung, 
breast, melanoma, and ovarian cancers 
in murine xenograft and allograft mod-
els. Their studies suggest that the prin-
cipal mechanism of the anti-S1P mAb is 
prevention of the proangiogenic effects 
of the blood-borne lipid mediator S1P.
As there are so many proang-
iogenic factors, including VEGF, bFGF, 
angiopoietin-1, IL-6, IL-8, and PDGF, 
among others, a critical question is how 
neutralization of this simple lysophos-
pholipid can have such dramatic effects 
on tumor angiogenesis. Some answers 
are provided by Visentin et al. (2006), 
as this S1P “sponge” not only blocked 
the functions of VEGF and bFGF in vivo, 
but also inhibited the release of VEGF, 
IL-6, and IL-8 in vivo and in vitro. Thus, 
either S1P is the central and obligatory 
mediator of the actions of proangiogen-
ic factors or its signaling is permissive 
for the angiogenic effects.
Complex crosstalk between S1P 
and growth and proangiogenic factor 
signaling pathways might explain these 
results (Figure 1). S1P by binding to 
S1P1 can transactivate growth factor 
receptor tyrosine kinases (RTK), such 
as VEGFR, EGFR, and PDGFR, through 
three mechanisms that are not mutu-
ally exclusive: (1) intracellular receptor 
crosstalk and direct phosphorylation of 
the RTK by protein tyrosine kinases; (2) 
induced production and/or secretion of 
the growth factors; and (3) by participa-
tion of S1P1 and RTK in a signalplex, 
either by direct receptor/receptor inter-
action or by binding of both receptors to 149
	 p r e v i e w sscaffolding protein. Conversely, binding 
of these growth factors to their RTKs 
can also translocate and activate SphK1 
(Pitson et al., 2005), leading to spatially 
restricted formation of S1P that in turn 
further activates canonical S1PR sign-
aling (“inside-out signaling”) (Hobson 
et al., 2001). In addition, these RTKs 
can also upregulate S1P1 (Igarashi 
et al., 2003). Thus, S1P might be the 
central controller of several amplifica-
tion loops. Moreover, interplay between 
the components of a signalplex that is 
necessary for tumor-driven angiogen-
esis may be much more intricate than 
linear transactivation of one receptor 
by another. This paradigm fits with the 
emerging view of the complexity and 
nonlinearity of signaling via S1PRs and 
RTKs, and of the importance of mem-
brane compartmentalization to signal 
transduction (Neve, 2005).
Another important question raised 
by the work of Sabbadini and col-
leagues is as follows: what is the source 
of active S1P that is being neutralized 
by their mAb? Serum contains signifi-
cant amounts of S1P, probably main-
ly arising by release from abundant 
platelet stores (Yatomi et al., 1995). 
However, most of this S1P is tightly 
bound to HDL and serum albumin, 
which protects it from degradation and 
decreases its bioavailability. Sabbadini 
and colleagues calculated that the 
dose of S1P mAb administered to mice 
that effectively blocked tumor growth 
reached blood levels that were about 3-
fold higher than S1P levels on a molar 
basis. The free concentration of S1P is 
determined by equilibria between for-
mation, elimination, binding, and com-150	partmentalization. It is possible that 
“free” S1P in serum is permissive for 
angiogenesis, and neutralizing it would 
block this necessary S1PR signaling. A 
less likely alternative is that the S1P-
mAb complex acts as an antagonist 
to block vital S1PR functions. Finally, 
a most attractive possibility is that it 
is S1P produced and secreted by the 
tumors themselves or by stromal cells 
or other cells attracted to the tumor that 
mediates the growth of tumor-feeding 
blood vessels. In support of this notion, 
SphK1 is upregulated in many tumor 
cells (French et al., 2003), and S1P1 
receptor expression is also induced in 
angiogenic vessels in vivo. However, 
it is still a mystery how the polar lipid 
S1P produced in cells by activation of 
SphK1 can cross the lipid bilayer and 
reach receptors on the surface of cells. 
If the anti-S1P mAb effectively sucks 
S1P from cells, it might have the added 
advantage of decreasing the intracel-
lular ratio between S1P and its pre-
cursors, sphingosine and ceramide, 
thus favoring cell growth arrest and 
apoptosis. In agreement, recent stud-
ies suggest that cytosolic S1P formed 
by SphK1 inhibits ceramide biosyn-
thesis, possibly as a cellular sensing 
mechanism to regulate levels of cera-
mide, and downregulation of SphK1 
enhances ceramide levels and apopto-
sis (Maceyka et al., 2005). This paper 
by Visentin et al. thus provides proof of 
concept that direct targeting of impor-
tant lipid signaling molecules is a novel 
strategy for development of new types 
of cancer treatments that could be use-
ful in combination with other treatment 
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